CELH
Celsius Holdings, Inc.
CELH has the edge over JBSS overall, supported by stronger fundamentals and stronger modeled upside.
JBSS
John B. Sanfilippo & Son, Inc.
JBSS has slightly lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
JBSS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
JBSS's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
JBSS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 12x | $56.22 | — |
| Forward | 12x | $56.22 | — |
| Cheap | 14x | $65.61 | +17% |
| Fair | 17x | $80.06 | +42% |
| Expensive | 19x | $88.55 | +58% |
Historical ranges are pointers, not guarantees.
JBSS has the edge over CELH in the historical PE scenario, which offers more potential upside but is not a forecast.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over JBSS on the outlook, with more favorable valuation and earnings expectations.
JBSS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Decline | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect JBSS's earnings and profitability to decline, with its revenue holding steady.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
JBSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.83 | +1.1% |
| Q3 2026 | $4.78 | -15% |
| Q2 2026 | $5.26 | +4.6% |
| Q1 2026 | $5.70 | +21% |
| Q4 2025 | $5.99 | +44% |
| Q3 2025 | $5.62 | +21% |
| Q2 2025 | $5.03 | -2.3% |
| Q1 2025 | $4.73 | -15% |
| Q4 2024 | $4.16 | -28% |
JBSS has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over JBSS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over JBSS on profitability, with a higher operating margin.
JBSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $288.1M | -3.5% |
| Q2 2026 | $280.4M | +4.2% |
| Q1 2026 | $281.8M | +8% |
| Q4 2025 | $314.8M | +4.6% |
| Q3 2025 | $298.7M | +8.1% |
| Q2 2025 | $269.1M | -0.2% |
| Q1 2025 | $260.9M | -4% |
| Q4 2024 | $301.1M | +3.4% |
JBSS's revenue grew through 2024 and has held roughly level since: $288M last quarter, down 3.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.7% | -2.3 points |
| Q2 2026 | 4.4% | -3.1 points |
| Q1 2026 | 8.4% | -2.4 points |
| Q4 2025 | 8.3% | +1.8 points |
| Q3 2025 | 9.1% | +2.9 points |
| Q2 2025 | 7.5% | +2 points |
| Q1 2025 | 11% | +4.1 points |
| Q4 2024 | 6.4% | -3.1 points |
JBSS's operating margin was 6.7% last quarter, down 2.3 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH has the edge over JBSS on cash flow, with more consistent year-over-year improvement.
JBSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.9M | -74% |
| Q2 2026 | $9.9M | -57% |
| Q1 2026 | -$21.5M | +$16.1M |
| Q4 2025 | $40M | +$42.7M |
| Q3 2025 | $7.3M | +$10.2M |
| Q2 2025 | $23M | -5.5% |
| Q1 2025 | -$37.6M | -$36.3M |
| Q4 2024 | -$2.7M | -108% |
JBSS's free cash flow has turned positive after two years mostly in the red: $30M over the past year.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over JBSS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
JBSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +59.4K shares |
| 1 year | +0.8% | +89.6K shares |
| 3 years | +1.4% | +162K shares |
| 5 years | +2.1% | +248K shares |
| Available history | +2.7% | +311K shares |
JBSS has 12M diluted shares, up 0.8% from a year ago.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over JBSS on leverage, with a lower net debt burden relative to earnings.
JBSS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.1x | Very low |
JBSS's net debt is less than a year of its operating earnings (EBITDA).
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
JBSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.9 | Neutral |
| Stochastic | 9.1 | Oversold |
JBSS's weekly RSI is 31 (neutral) and its Stochastic is 9 (oversold).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
JBSS PE vs Consumer Defensive Sector
| Metric | JBSS | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 19x | 40% below |
| PE % | 1 | 18 | 17 pts below |
JBSS has the edge over CELH on valuation relative to its sector.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has the edge over JBSS on trend strength, trading above more of its moving averages.
JBSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.7 | 10% below |
| 20 week MA | $72.6 | 23% below |
| 50 week MA | $75.5 | 26% below |
| 100 week MA | $72.1 | 22% below |
| 200 week MA | $85.9 | 35% below |
JBSS is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
JBSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $91.5 | $78.6 | -14% |
| 2021 | $78.6 | $89.3 | +14% |
| 2022 | $89.3 | $81.2 | -9.1% |
| 2023 | $81.2 | $103.0 | +27% |
| 2024 | $103.0 | $86.0 | -17% |
| 2025 | $86.0 | $71.7 | -17% |
| 2026 YTD | $71.7 | $56.2 | -22% |
JBSS has the edge over CELH on returns for 2026, with the stronger performance.